Your bone marrow is a soft, spongy tissue hidden inside your bones — and it’s arguably the hardest-working organ you never think about. Every single day, it produces roughly 500 billion blood cells, including the red blood cells that carry oxygen, the white blood cells that fight infection, and the platelets that stop you from bleeding. When bone marrow fails, the consequences are severe and often life-threatening.
This guide covers bone marrow functions, disorders, and treatments in detail — from how normal hematopoiesis works, to the major diseases that disrupt it, to the transplant and drug therapies used to restore it. Whether you’re a patient recently diagnosed with a bone marrow condition, a caregiver, or a medical student, this is what you actually need to know.
What Does Bone Marrow Do? The Core Functions
Bone marrow is the body’s blood cell factory. Through a process called hematopoiesis, a small population of hematopoietic stem cells (HSCs) differentiates into every type of blood cell your body needs. These stem cells are remarkably versatile — a single HSC can give rise to red cells, white cells, and platelets.
There are two types of bone marrow, and they serve different roles:
| Feature | Red Bone Marrow | Yellow Bone Marrow |
|---|---|---|
| Primary function | Active blood cell production (hematopoiesis) | Fat storage and energy reserve |
| Main cell types | Hematopoietic stem cells, developing blood cells | Adipocytes (fat cells) |
| Location in adults | Pelvis, sternum, vertebrae, ribs, skull, proximal femur | Long bone shafts (femur, tibia, humerus) |
| Changes with age | Gradually replaced by yellow marrow after ~age 7 | Increases throughout adulthood |
| Can it convert? | Yes — converts to yellow when demand drops | Yes — reverts to red during severe anemia or blood loss |
In newborns, nearly all bone marrow is red and actively producing cells. By adulthood, roughly 50% has converted to yellow marrow. This conversion is reversible — in emergencies like massive hemorrhage or severe anemia, yellow marrow can reactivate and start producing blood cells again.
Major Bone Marrow Disorders
When bone marrow malfunctions, it either produces too few cells (bone marrow failure), too many abnormal cells (myeloproliferative disorders), or cancerous cells that crowd out normal production. Here are the most significant conditions:
Aplastic Anemia
Aplastic anemia occurs when the bone marrow stops producing enough of all three blood cell lines — red cells, white cells, and platelets (a state called pancytopenia). It affects about 2 per million people annually in Western countries, though rates are 2-3 times higher in East Asia. Roughly 75% of cases are autoimmune in origin, where the body’s own T-cells attack marrow stem cells. Without treatment, severe aplastic anemia has a mortality rate exceeding 70% within two years.
Leukemia
Leukemia is a group of cancers where abnormal white blood cells proliferate uncontrollably in the marrow. The four main types — ALL, AML, CLL, and CML — vary dramatically in prognosis. AML is the most common acute leukemia in adults (about 20,000 new U.S. cases per year), while ALL is the most common childhood cancer. Survival rates range from over 90% for childhood ALL down to roughly 30% five-year survival for AML in older adults.
Myelodysplastic Syndromes (MDS)
MDS represents a group of disorders where bone marrow produces defective blood cells that die prematurely. It primarily affects people over 65 and carries a significant risk (approximately 30%) of transforming into AML. The marrow is often hypercellular — packed with cells — but those cells are dysplastic and dysfunctional.
Multiple Myeloma
Multiple myeloma is a cancer of plasma cells within the marrow. It causes bone destruction, kidney damage, anemia, and immune suppression. Median age at diagnosis is 69, and approximately 35,000 new cases are diagnosed annually in the U.S. Five-year survival has improved significantly — from about 30% in the 1990s to over 55% today — thanks to novel drug therapies.
Primary Myelofibrosis
In primary myelofibrosis, the marrow is progressively replaced by scar tissue (fibrosis), forcing blood cell production to shift to the spleen and liver (extramedullary hematopoiesis). This leads to massive spleen enlargement, severe anemia, and constitutional symptoms like drenching night sweats and weight loss. Median survival ranges from 2 to 11 years depending on risk category.
How Bone Marrow Disorders Are Diagnosed
Diagnosis typically starts with a complete blood count (CBC) that reveals abnormal cell numbers. But the definitive test is a bone marrow biopsy — usually taken from the posterior iliac crest (back of the hip bone). This involves two components:
- Aspirate: A liquid sample of marrow cells examined under the microscope for cell morphology, blast counts, and special stains
- Core biopsy: A solid cylinder of bone and marrow tissue that shows architecture, cellularity, and fibrosis
Additional testing often includes flow cytometry (identifies cell surface markers), cytogenetics (detects chromosomal abnormalities), and molecular testing for mutations like JAK2, CALR, BCR-ABL, FLT3, and NPM1. These molecular markers increasingly guide treatment selection.
Current Treatments for Bone Marrow Disorders
Bone Marrow (Stem Cell) Transplant
An allogeneic stem cell transplant remains the only curative option for many bone marrow disorders, including severe aplastic anemia, high-risk MDS, AML, and myelofibrosis. The patient’s diseased marrow is destroyed with chemotherapy (and sometimes radiation), then replaced with donor stem cells. For severe aplastic anemia in patients under 40 with a matched sibling donor, transplant achieves long-term survival rates of 80-90%.
The major risks include graft-versus-host disease (GVHD), where donor immune cells attack the recipient’s tissues, and transplant-related mortality, which ranges from 10-30% depending on age, donor match, and disease status.
Drug Therapies
- Immunosuppressive therapy (IST): Horse ATG plus cyclosporine is standard for aplastic anemia patients who aren’t transplant candidates — response rates are approximately 60-70%
- Hypomethylating agents: Azacitidine and decitabine are first-line for higher-risk MDS, improving survival and delaying AML transformation
- JAK inhibitors: Ruxolitinib (Jakafi) dramatically reduces spleen size and symptom burden in myelofibrosis, though it doesn’t eliminate the underlying disease
- Targeted therapies: Drugs like venetoclax (BCL-2 inhibitor), midostaurin (FLT3 inhibitor), and ivosidenib (IDH1 inhibitor) have transformed AML treatment in recent years
- Lenalidomide: Particularly effective for MDS with deletion 5q, achieving transfusion independence in about 67% of patients
Supportive Care
Regardless of the primary treatment, most patients with bone marrow disorders need aggressive supportive care: red blood cell transfusions for anemia, platelet transfusions for bleeding risk, growth factors like erythropoietin or G-CSF, and prophylactic antibiotics and antifungals during periods of severe neutropenia.
When to See a Doctor
Don’t wait if you’re experiencing any combination of these symptoms:
- Persistent, unexplained fatigue that doesn’t improve with rest
- Frequent infections or fevers without obvious cause
- Easy bruising or bleeding that seems disproportionate to the injury
- Petechiae — tiny red or purple dots on the skin, especially on the lower legs
- Unexplained bone pain, particularly in the back, ribs, or pelvis
- Unintentional weight loss or drenching night sweats
Ask your doctor for a CBC with differential as a first step. If results are abnormal, a referral to a hematologist is warranted — and don’t let anyone tell you to “wait and recheck in three months” if your counts are significantly abnormal.
Frequently Asked Questions
Can bone marrow repair itself?
Yes, in many cases. Bone marrow has remarkable regenerative capacity. After chemotherapy, for example, marrow typically recovers within 2-4 weeks. In autoimmune aplastic anemia treated with immunosuppression, the marrow can gradually restore normal blood cell production over months. However, in conditions like myelofibrosis where structural scarring has occurred, self-repair is limited without intervention.
Is a bone marrow biopsy painful?
Most patients describe the aspirate portion as a brief, deep pressure or pulling sensation lasting a few seconds — uncomfortable but tolerable. The core biopsy is usually less painful than the aspirate. Local anesthesia is always used, and many centers now offer conscious sedation. The entire procedure takes about 15-20 minutes, and soreness at the biopsy site typically resolves within a few days.
What’s the difference between a bone marrow transplant and a stem cell transplant?
They’re essentially the same concept — replacing diseased marrow with healthy stem cells. The difference is the source. Stem cells can be harvested directly from the donor’s bone marrow (traditional transplant), collected from peripheral blood after mobilization with G-CSF (the most common method today), or obtained from umbilical cord blood. Peripheral blood stem cell collection now accounts for roughly 75% of allogeneic transplants.
How long does it take to recover from a bone marrow transplant?
Engraftment — when the new stem cells start producing detectable blood cells — typically occurs 14-21 days after transplant. But full immune recovery takes 6-12 months or longer. Most patients spend 3-4 weeks in the hospital and require 6-12 months before returning to normal activities. Chronic GVHD can extend recovery significantly.
Can you live without bone marrow?
No. Without functioning bone marrow, your body cannot produce the blood cells needed for oxygen transport, immune defense, or clotting. Complete bone marrow failure is fatal without treatment — which is precisely why conditions like severe aplastic anemia are medical emergencies that require urgent hematology referral.
